Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial – Authors’ reply

By sjmartinez • July 29, 2024

Rugo HS, Bardia A, Tolaney S. Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial - Authors' reply. Lancet. 2024 Jul 27;404(10450):339-340. doi: 10.1016/S0140-6736(24)01049-3. PMID: 39067902.

Tags: Hematology/Oncology, Publications

Risk of severe immune-related adverse events in cancer patients with pre-existing autoimmunity receiving immune checkpoint inhibitor therapy

Isaacs DJ, Kathuria-Prakash N, Hilder R, Lechner MG, Drakaki A. Risk of severe immune-related adverse events in cancer patients with pre-existing autoimmunity receiving immune checkpoint[...]

Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract Cancer

Bang YH, Lee CK, Bang K, Kim HD, Kim KP, Jeong JH, Park I, Ryoo BY, Lee DK, Choi HJ, Chung T, Jeon SH, Shin[...]

Feasibility of a blood pressure telemedicine program in the virtual age

Sreekrishnan A, Lansberg M, Singer AE, Tennant RS, Howard M, Buncom J, Castillo M, Rajasekhar V, Kraler L. Feasibility of a blood pressure telemedicine program[...]